Skip to main content
. Author manuscript; available in PMC: 2021 Mar 1.
Published in final edited form as: Clin Pharmacol Ther. 2019 Nov 1;107(3):563–570. doi: 10.1002/cpt.1641

Figure 1.

Figure 1.

A) Voriconazole (VCZ) trough concentrations stratified by CYP2C19 diplotype and dosage were compared using a liner-mixed-effects model fitted to log-transformed concentrations. VCZ concentrations were also compared between CYP2C19 rapid metabolizers receiving the standard VCZ dosage (200 mg twice daily [BID]) and the interventional dosage (300 mg BID). B) Wilcoxon signed-rank test compared trough concentrations between nine CYP2C19 rapid metabolizers who receive both VCZ 200 mg and 300 mg BID. Box plots represent the median and interquartile range, and data points with darker outlines represent >1 trough concentration of the same value.